Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
- Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape
- Brings over 15 years of global oncology and hematology leadership, advancing over 10 radioligands across the development spectrum, from preclinical to Phase III
Oslo, Norway and Cambridge, Massachusetts — 3 December 2025 — Actithera (“the Company”), a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the appointment of Darshan Dalal, M.D., PhD, MPH as Chief Medical Officer (CMO). In this role, Dr. Dalal will lead the clinical strategy and build the clinical development organization as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic and builds its pipeline of differentiated precision-engineered radiopharmaceuticals.
